Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck
Nuklearmedizin - NuclearMedicine · 01.06.2026 · 65 (03) · 217-222
DOI: 10.1055/a-2800-7670 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nuklearmedizin - NuclearMedicine, erschienen am 01.06.2026. Verfasst von Sophie C Siegmund und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, University Hospital, LMU Munich, Germany, Munich. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Carcinoma, Squamous Cell, Theranostic Nanomedicine. Die Arbeit nennt 64 Literaturangaben.
Abstract (Originalsprache)
This review aims to explore the evolving field of theranostics in oncology, focusing on its potential application to head and neck squamous cell carcinoma (HNSCC). Specifically, it examines the integration of molecular imaging and radionuclide therapy in the context of theranostics. A comprehensive review of current literature was conducted to evaluate the state-of-the-art theranostic approaches in HNSCC. The review includes an analysis of established and emerging molecular targets relevant to HNSCC, as well as the potential for future theranostic developments. The integration of theranostic principles into head and neck oncology is gaining momentum, with increasing interest in novel targets in the context of theranostics. Although [18F]FDG PET/CT still remains the dominant imaging modality in HNSCC, the application of novel radiotracers for imaging and radionuclide therapy holds considerable promise. Theranostics represents a promising future for head and neck oncology, offering the potential for personalized, biology-driven diagnostic and therapeutic strategies. While many emerging approaches are still under investigation, the combination of molecular imaging and targeted radionuclide therapy may significantly enhance the treatment of HNSCC, providing more precise and effective patient care in the future.1.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Nuclear Medicine, University Hospital, LMU Munich, Germany, Munich.
- University Hospital Würzburg, Department of Nuclear Medicine, Germany, Würzburg.
- University Hospital Würzburg, Department of Nuclear Medicine and Comprehensive Heart Failure Center, Germany, Würzburg.
- Faculty of Medicine Okayama University, Dentistry and Pharmaceutical Sciences, Japan, Okayama.
- LMU University Hospital, Department of Otorhinolaryngology, Germany, Munich.
- Comprehensive Cancer Center (CCC) MunichLMU, LMU University Hospital Munich, Germany, Munich.
ORCID-Profile: Sophie C Siegmund
Zitieren
APA
Siegmund, S. C., Serfling, S. E., Higuchi, T., Buck, A., Canis, M., Reichel, C. A., & Werner, R. A. (2026). Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck. Nuklearmedizin - NuclearMedicine, 65(03), 217-222. https://doi.org/10.1055/a-2800-7670
Vancouver
Siegmund SC, Serfling SE, Higuchi T, Buck A, Canis M, Reichel CA, et al. Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck. Nuklearmedizin - NuclearMedicine. 2026;65(03):217-222. doi:10.1055/a-2800-7670
BibTeX
@article{Siegmund2026,
author = {Siegmund, Sophie C and Serfling, Sebastian E and Higuchi, Takahiro and Buck, Andreas and Canis, Martin and Reichel, Christoph A and Werner, Rudolf A},
title = {Emerging Theranostic Targets in Squamous Cell Carcinoma of the Head and Neck},
journal = {Nuklearmedizin - NuclearMedicine},
year = {2026},
volume = {65},
number = {03},
pages = {217--222},
doi = {10.1055/a-2800-7670}
}
EUVIMED